When putting together your watch list, focus on stocks with an 80 or higher RS Rating. LENZ Therapeutics LENZ now meets that criteria, with a jump from 79 to 85 Friday. Please watch the video at ...

LENZ Therapeutics, Inc. (NASDAQ:LENZ) saw its stock rise 6.1% in premarket trading following the release of its ...

LENZ Therapeutics' LNZ100 leads presbyopia treatment with superior efficacy and FDA approval likely by Aug. 2025. Learn more ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

LENZ Therapeutics’ product candidate addresses a widespread condition affecting approximately 1.8 billion people globally, highlighting the potential market size and opportunity for the company.

“LENZ Therapeutics is strongly positioned with Phase 3 lead program, addressing a very large target market with near-term, high potential, value-inflecting milestones and a well-credentialed ...